Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
RPRX
#573
Royalty Pharma plc Class A Ordinary Shares
48.820
0
USD
+0.81%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+0.81%
Changement Mensuel
+6.52%
Evolution sur 6 mois
+31.03%
Changement Annuel
+31.03%
Clôture Précédente
48.430
0
Open
48.820
0
Bid
Ask
Low
48.820
0
High
48.820
0
Volume
203
Marchés
Actions des Marchés US
Soins de Santé
RPRX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
388.13 M
432.96 M
443.17 M
446.69 M
433.32 M
428.42 M
—
Valuation ratios
Enterprise value
29.42 B
27.35 B
25.83 B
21.89 B
20.17 B
27.82 B
100.77 B
Price to earnings ratio
31.16
39.04
394
11.17
13.36
21.71
70.31
Price to sales ratio
8.85
7.22
7.71
7.24
6.7
9.17
34.98
Price to cash flow ratio
9.24
8.19
8.05
5.7
5.47
8.76
32.76
Price to book ratio
6.31
4.19
3.07
2.61
2.18
3.37
5.6
Enterprise value to EBITDA ratio
168.52 K
113.31 K
577.4 K
109.36 K
120.6 K
150.62 K
509.31 K
Profitability ratios
Return on assets %
0.06
0.04
0
0.07
0.05
0.04
0.04
Return on equity %
0.1
0.06
0
0.11
0.08
0.08
0.08
Return on invested capital %
45.75
39.11
7.99
38.15
30.83
34.06
34.9
Gross margin %
92.64
100.56
68.24
75.24
63.21
111.34
447.42
Operating margin %
75.17
62.49
13.73
63.37
57.1
65.58
262.81
EBITDA margin %
84.97
93.29
18.52
65.6
53.88
62.24
248.14
Net margin %
45.94
27.07
1.91
48.2
37.95
32.42
128.9
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.76
16.81
2.19
7.9
1.44
2.4
8.7
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.13
0.14
0.13
0.14
0.13
0.13
0.13
Solvency ratios
Debt to assets ratio
0.36
0.41
0.36
0.37
0.36
0.44
1.64
Debt to equity ratio
1.21
1.23
1.09
0.94
0.95
1.33
4.76
Long term debt to total assets ratio
0.36
0.41
0.36
0.37
0.36
0.44
1.64
Long term debt to total equity ratio
1.21
1.23
1.09
0.94
0.95
1.32
4.75
Per share metrics
Operating cash flow per share
3.35
3.32
4.9
4.96
4.66
4.41
4.4
EBIT per share
2.63
2.36
0.7
2.47
2.18
2.76
2.75
EBITDA per share
2.97
3.52
0.95
2.56
2.05
2.62
2.63
Total debt per share
9.58
11.69
13.97
10.18
11.13
15.22
54.5
Cash per share
3.4
3.61
3.96
0.82
1.66
1.13
5.89
Net current asset value per share
4.44
4.74
5.83
2.11
3.03
2.71
11.9
Tangible book value per share
12.76
13.91
12.85
10.83
11.69
9.84
40.86
Working capital per share
3.94
4.46
3.17
1.85
0.92
1.58
5.64
Book value per share
7.94
9.51
12.85
10.83
11.69
11.47
45.8
Nouvelles
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside (RVMD)
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
L’action Royalty Pharma atteint un sommet de 52 semaines à 47,87$
TD Cowen réitère sa recommandation d’achat sur Royalty Pharma
Denali Therapeutics reçoit 200 millions $ suite à l’approbation de la FDA
Royalty Pharma engage 500 millions $ pour un médicament auto-immun de J&J
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
Royalty Pharma nomme Lucas Glass à la tête de l’intelligence artificielle
Royalty Pharma nomme Greg Butz au poste de vice-président exécutif